Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309902 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Joon Young Yoon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea. Hauptthemen laut MEDLINE: Pyrazinamide, Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Korea National Institute of Health, Chonnam National University Hospital Biomedical Research Institute..
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Pyrazinamide (PZA) usage has been associated with adverse drug reactions, prompting its avoidance in treating elderly tuberculosis (TB) patients. This study aims to examine whether the administration of PZA is associated with poor outcomes during TB treatment among elderly individuals.
Methods
A retrospective analysis was undertaken on data collected from a prospective cohort conducted between July 2019 and June 2023, which involved tuberculosis patients from 18 institutions across the Republic of Korea. The study aimed to assess the impact of PZA on the incidence of serious adverse events (SAEs), medication interruptions, and becoming loss to follow-up (LTFU) during standard short courses of TB treatment in elderly (≥65 years old) patients.
Results
PZA was administered to 356 of 390 elderly patients (91.3%), and 98 of the 390 (25.1%) experienced SAEs. Treatment success was significantly lower in patients not treated with PZA compared to those who received PZA (64.7% vs 89.9%, p < 0.001). The incidence of SAEs, medication interruption, or LTFU was higher in patients not given PZA compared those who received PZA (52.9% vs. 27.2%, p = 0.002). A multivariate logistic regression analysis, factoring in covariates such as age, comorbidities, and baseline laboratory data, revealed that PZA was not a risk factor for SAEs, medication interruption, or LTFU in TB treatment (odds ratio [OR] 0.457, 95% confidence interval [CI] 0.201–1.041).
Conclusion
Treating elderly TB patients with PZA did not increase the incidence of SAEs, medication interruptions, or LTFU during the standard short course of TB treatment. Therefore, considering its potential advantages, incorporating PZA into the treatment regimen for elderly TB patients may be advisable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Jinsoo Min, Yong-Soo Kwon
Förderung
- NIH HHS
- Korea National Institute of Health
- Chonnam National University Hospital Biomedical Research Institute.
Zitieren
APA
Yoon, J. Y., Kim, T. O., Kim, J. S., Kim, H. W., Lee, E. G., Jung, S. S., Oh, J. Y., Kim, J. W., Lee, S. H., Kim, S., Kim, S. H., Park, Y., Min, J., & Kwon, Y. S. (2024). Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0309902
Vancouver
Yoon JY, Kim TO, Kim JS, Kim HW, Lee EG, Jung SS, et al. Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0309902
BibTeX
@article{Yoon2024,
author = {Yoon, Joon Young and Kim, Tae-Ok and Kim, Ju Sang and Kim, Hyung Woo and Lee, Eung Gu and Jung, Sung Soo and Oh, Jee Youn and Kim, Jin Woo and Lee, Sang Haak and Kim, Seunghoon and Kim, Sun-Hyung and Park, Yeonhee and Min, Jinsoo and Kwon, Yong-Soo},
title = {Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309902}
}
EUVIMED